6CM
VTVT icon

683 Capital Management’s vTv Therapeutics VTVT Stock Holding History

683 Capital Management’s Portfolio VTVT Stock Details VTVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-16,000
Closed -$635K – 242
2026
Q1 		$635K Sell
16,000
-2,268
-12% -$82.3K 0.03% 168
2025
Q4 		$731K Buy
+18,268
New +$509K 0.03% 168

Other funds holding VTVT

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

683 Capital Management's VTVT Position: Q2 2026 in Review

683 Capital Management sold out of vTv Therapeutics (VTVT) in Q2 2026, closing a stake of 16,000 shares — an estimated $635K sold.

683 Capital Management first reported a position in VTVT in Q4 2025 and held it in 2 quarters. The position peaked at $731K in Q4 2025. 45 funds tracked by Wall St. Rank hold VTVT as of Q2 2026.

  • 683 Capital Management reported no remaining vTv Therapeutics position as of Q2 2026 after selling out during the quarter.
  • 683 Capital Management sold 16,000 vTv Therapeutics shares in Q2 2026, an estimated $635K.
  • 683 Capital Management first reported a position in vTv Therapeutics in Q4 2025 and held it in 2 quarters.
  • 683 Capital Management's vTv Therapeutics position peaked at $731K in Q4 2025.
  • 45 funds tracked by Wall St. Rank held vTv Therapeutics as of Q2 2026.

Based on 683 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.